Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Conference Coverage

Sequencing Vemurafenib, Cobimetinib, and Atezolizumab for Patients With High-Risk Melanoma

 

Paolo Ascierto, MD, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy, discusses primary results from the phase 2 NEO-TIM trial which sought to determine the optimal sequencing of vemurafenib, cobimetinib, and atezolizumab among patients with patients with high-risk melanoma. 


Source: 

Ascierto P. Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results. Presented at the ASCO Annual Meeting. May 31 – June 4, 2024; Chicago, IL. Abstract #LBA9513

© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates. 

Advertisement

Advertisement

Advertisement

Advertisement